| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/07/2013 | WO2013017656A1 Antagonists of ribonucleases for treating obesity |
| 02/07/2013 | WO2013017637A1 Selective inhibition of malt1 protease by phenothiazine derivatives |
| 02/07/2013 | WO2013017619A1 Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta |
| 02/07/2013 | WO2013017600A1 Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one |
| 02/07/2013 | WO2013017582A1 Acetone solvate of ivabradine hydrochloride |
| 02/07/2013 | WO2013017571A1 Aqueous solutions of lipophilic substances, in particular medicinal solutions |
| 02/07/2013 | WO2013017551A1 Method for increasing the intraocular pressure in an animal |
| 02/07/2013 | WO2013017548A1 1,4-diaryl-2-azetidinones with anti-tumoral activity |
| 02/07/2013 | WO2013017542A1 Method for preventing or treating memory impairment and pharmaceutical compositions useful therefor |
| 02/07/2013 | WO2013017480A1 Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| 02/07/2013 | WO2013017479A1 Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| 02/07/2013 | WO2013017475A1 New use of l-histidine and derivatives thereof |
| 02/07/2013 | WO2013017461A1 Pyridin-2(1h)-one derivatives as jak inhibitors |
| 02/07/2013 | WO2013017374A1 Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring |
| 02/07/2013 | WO2013017254A1 Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccaride ps-i, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools |
| 02/07/2013 | WO2013017242A1 Tamper-resistant tablet providing immediate drug release |
| 02/07/2013 | WO2013017234A1 Tamper-resistant tablet providing immediate drug release |
| 02/07/2013 | WO2013017233A1 Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| 02/07/2013 | WO2013017136A1 Treatment of cognitive impairment |
| 02/07/2013 | WO2013017100A1 Imatinib mesylate tablet |
| 02/07/2013 | WO2013017073A1 Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament |
| 02/07/2013 | WO2013017071A1 Alicyclic[c] benzopyrone derivatives and uses thereof |
| 02/07/2013 | WO2013017068A1 Substituted benzopyrone derivative and use thereof |
| 02/07/2013 | WO2013017063A1 Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof |
| 02/07/2013 | WO2013017026A1 Hcv protease inhibitors |
| 02/07/2013 | WO2013016999A1 Heteroaryl-pyrimidine derivatives, and preparation method therefor and use thereof |
| 02/07/2013 | WO2013016807A1 Insulin secretion promoting agents |
| 02/07/2013 | WO2012174243A8 D -serine for the treatment of visual system disorders |
| 02/07/2013 | WO2012174049A3 Compositions and methods for controlling neuronal excitation |
| 02/07/2013 | WO2012156997A3 Multi-particulate pharmaceutical composition |
| 02/07/2013 | WO2012145575A3 Therapy for leukemia |
| 02/07/2013 | WO2012145129A3 Molecular subtyping, prognosis and treatment of prostate cancer |
| 02/07/2013 | WO2012142457A3 Macrolactam compounds and methods for the treatment of malaria |
| 02/07/2013 | WO2012142093A3 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| 02/07/2013 | WO2012123482A3 Isoxazolidine derivatives |
| 02/07/2013 | WO2012016699A8 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 02/07/2013 | WO2012009778A3 A stable topical composition and a process for producing a stable topical composition |
| 02/07/2013 | WO2011139246A9 Topical or injectable composition comprising humic acid salts and polyvinylpyrrolidone for the treatment of skin diseases |
| 02/07/2013 | WO2011085063A9 Immune modulators relating to foxo3a |
| 02/07/2013 | WO2011014793A3 Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof |
| 02/07/2013 | WO2005051352A8 Veterinary compositions for treating mastitis |
| 02/07/2013 | US20130035754 Drug-delivery endovascular stent and method of forming the same |
| 02/07/2013 | US20130035635 Carrier-linked carbamate prodrug linkers |
| 02/07/2013 | US20130035398 Functionalized fullerenes as a biomass stimulant and a life extension agent |
| 02/07/2013 | US20130035397 Anti-Viral Compounds |
| 02/07/2013 | US20130035394 Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making |
| 02/07/2013 | US20130035393 Method for treating schizophrenia |
| 02/07/2013 | US20130035392 Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex |
| 02/07/2013 | US20130035391 Felbinac-Containing Transdermally Absorbable Preparation |
| 02/07/2013 | US20130035390 Treatment of multiple sclerosis |
| 02/07/2013 | US20130035389 Methods for treating myelodysplastic syndrome with ezatiostat |
| 02/07/2013 | US20130035388 Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex |
| 02/07/2013 | US20130035387 Sarms and method of use thereof |
| 02/07/2013 | US20130035386 Bis[thiohydrazide amide] compounds for treating leukemia |
| 02/07/2013 | US20130035385 Orally dispersible tablet |
| 02/07/2013 | US20130035384 Orally dispersible tablet |
| 02/07/2013 | US20130035383 Liquid/liquid extraction |
| 02/07/2013 | US20130035382 Anti-Viral Compounds |
| 02/07/2013 | US20130035381 Virus-inactivating composition containing low-molecular weight compound and arginine |
| 02/07/2013 | US20130035380 Process for selective extraction of bioactive and bioavailable cinnamon polyphenols and procyanidin oligomers and a stable composition thereof |
| 02/07/2013 | US20130035379 Compositions for Inhibiting Protine-Directed Protein Kinase Fa/Glycogen Synthesis Kinase 3 Alpha and Use Thereof |
| 02/07/2013 | US20130035378 Film delivery system for tetrahydrolipstatin |
| 02/07/2013 | US20130035377 Tranylcypromine derivatives as inhibitors of histone demethylases lsd1 and/or lsd2 |
| 02/07/2013 | US20130035376 MCP-1 binding nucleic acids |
| 02/07/2013 | US20130035375 Gene re-cycling |
| 02/07/2013 | US20130035374 MicroRNA induction of pluripotential stem cells and uses thereof |
| 02/07/2013 | US20130035373 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
| 02/07/2013 | US20130035372 Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
| 02/07/2013 | US20130035371 Lipid formulated dsrna targeting the pcsk9 gene |
| 02/07/2013 | US20130035370 Compositions and methods for modulation of lmna expression |
| 02/07/2013 | US20130035369 Double strand compositions comprising differentially modified strands for use in gene modulation |
| 02/07/2013 | US20130035368 Oligonucleotide compounds comprising non-nucleotide overhangs |
| 02/07/2013 | US20130035367 Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndrome |
| 02/07/2013 | US20130035366 Modulation of hepatitis b virus (hbv) expression |
| 02/07/2013 | US20130035365 Anti-sense oligonucleotides targeted against exon 9 of IL-23R alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases |
| 02/07/2013 | US20130035364 Benzylidene-indolinone compounds and their medical use |
| 02/07/2013 | US20130035363 Thalidomide Analogs |
| 02/07/2013 | US20130035362 Stable Anti-inflammatory Solutions for Injection |
| 02/07/2013 | US20130035360 Novel water soluble furoxan derivatives having antitumor activity |
| 02/07/2013 | US20130035359 Compositions containing aromatic aldehydes and their use in treatments |
| 02/07/2013 | US20130035358 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| 02/07/2013 | US20130035357 Compositions and Methods for Preventing Joint Destruction in Osteoarthritis |
| 02/07/2013 | US20130035356 Crystal of diamine derivative and method of producing same |
| 02/07/2013 | US20130035355 Prasugrel in micronized, crystalline form and pharmaceutical composition thereof |
| 02/07/2013 | US20130035354 Aryl pyridine as aldosterone synthase inhibitors |
| 02/07/2013 | US20130035353 Drugs for the treatment of sarcoglycanopathies |
| 02/07/2013 | US20130035352 Gaba conjugates and methods of use thereof |
| 02/07/2013 | US20130035351 Oximes For Treatment Of Peripheral And Central Nervous System Exposure To Acetyl Cholinesterase Inhibitors |
| 02/07/2013 | US20130035350 Novel Quinazoline Derivatives |
| 02/07/2013 | US20130035349 Pyrazolopyrimidinone kinase inhibitor |
| 02/07/2013 | US20130035348 Antimetastatic compounds |
| 02/07/2013 | US20130035347 Aromatic bycyclic derivatives as cxcr4 receptor modulators |
| 02/07/2013 | US20130035346 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors |
| 02/07/2013 | US20130035345 Solid dispersion formulations and methods of use thereof |
| 02/07/2013 | US20130035344 Pharmaceutical composition for oral administration |
| 02/07/2013 | US20130035343 Combination of organic compounds |
| 02/07/2013 | US20130035342 Compound Suitable for the Treatment of Synucleopathies |
| 02/07/2013 | US20130035341 Macrocyclic integrase inhibitors |
| 02/07/2013 | US20130035340 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| 02/07/2013 | US20130035339 Apoptosis signal-regulating kinase inhibitors |